Search

Your search keyword '"Ruckdeschel, Anna"' showing total 15 results
Start Over Author "Ruckdeschel, Anna"
15 results on '"Ruckdeschel, Anna"'

1. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

Author

Leipold, Alexander M., Werner, Rudolf A., Düll, Johannes, Jung, Pius, John, Mara, Stanojkovska, Emilia, Zhou, Xiang, Hornburger, Hannah, Ruckdeschel, Anna, Dietrich, Oliver, Imdahl, Fabian, Krammer, Tobias, Knop, Stefan, Rosenwald, Andreas, Buck, Andreas, Sander, Leif Erik, Einsele, Hermann, Kortüm, K. Martin, Saliba, Antoine-Emmanuel, and Rasche, Leo

Published
2023
Full Text
View/download PDF

2. Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.

Author

Zhou, Xiang, Wagner, Vivien, Scheller, Lukas, Stanojkovska, Emilia, Riedhammer, Christine, Xiao, Xianghui, Steinhardt, Maximilian Johannes, Vogt, Cornelia, Nerreter, Silvia, Eisele, Florian, John, Mara, Munawar, Umair, Kadel, Sofie‐Katrin, Mersi, Julia, Ruckdeschel, Anna, Schimanski, Sven, Haertle, Larissa, Waldschmidt, Johannes Moritz, Han, Seungbin, and Topp, Max

Subjects
MULTIPLE myeloma, CYTOPENIA, T cells, LEUCOPENIA, HYPERFERRITINEMIA
Abstract

Summary: Biomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients treated with BCMA‐targeted CAR T cells, and then divided them into three groups: (i) baseline (before leukapheresis), (ii) ≤day+30, and (iii) >day+30 after CAR T‐cell therapy. We evaluated laboratory data and performed flow cytometry to determine the (CAR) T‐cell subsets. Baseline hyperferritinaemia was a risk factor for long‐lasting grade ≥3 anaemia (r = 0.47, p < 0.001) and thrombocytopenia (r = 0.44, p = 0.002) after CAR T‐cell therapy. Low baseline haemoglobin (Hb) and PLT were associated with long‐lasting grade ≥3 anaemia (r = −0.56, p < 0.001) and thrombocytopenia (r = −0.44, p = 0.002) respectively. We observed dynamics of CAR‐negative T‐cell subsets following CAR T‐cell infusion. In the late phase after CAR T‐cell therapy (>day+30), CD4Tn frequency correlated with anaemia (r = 0.41, p = 0.0014) and lymphocytopenia was related to frequencies of CD8+ T cells (r = 0.72, p < 0.001) and CD8Teff (r = 0.64, p < 0.001). CD4Tcm frequency was correlated with leucocytopenia (r = −0.49, p < 0.001). In summary, preexisting cytopenias and hyperferritinaemia indicated long duration of grade ≥3 post‐CAR T‐cell cytopenias. Prolonged cytopenia may be related to immune remodelling with a shift in the CAR‐negative T‐cell subsets following CAR T‐cell therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma

Author

Leipold, Alexander M., primary, Werner, Rudolf A., additional, Düll, Johannes, additional, Jung, Pius, additional, John, Mara, additional, Stanojkovska, Emilia, additional, Zhou, Xiang, additional, Hornburger, Hannah, additional, Ruckdeschel, Anna, additional, Dietrich, Oliver, additional, Imdahl, Fabian, additional, Krammer, Tobias, additional, Knop, Stefan, additional, Rosenwald, Andreas, additional, Buck, Andreas, additional, Sander, Leif Erik, additional, Einsele, Hermann, additional, Kortüm, K. Martin, additional, Saliba, Antoine-Emmanuel, additional, and Rasche, Leo, additional

Published
2022
Full Text
View/download PDF

4. Pseudoprogression and Sarcoidosis-like Phenomena after CART-Cells and Bispecific Antibodies in Multiple Myeloma

Author

Leipold, Alexander, primary, Werner, Rudolf, additional, Duell, Johannes, additional, Jung, Pius, additional, John, Mara, additional, Stanojkovska, Emilia, additional, Zhou, Xiang, additional, Ruckdeschel, Anna, additional, Dietrich, Oliver, additional, Imdahl, Fabian, additional, Krammer, Tobias, additional, Buck, Andreas, additional, Mersi, Julia, additional, Einsele, Hermann, additional, Kortuem, K. Martin, additional, Saliba, Antoine-Emmanuel, additional, and Rasche, Leo, additional

Published
2022
Full Text
View/download PDF

6. Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM

Author

Truger, Marietta S., Duell, Johannes, Zhou, Xiang, Heimeshoff, Larissa, Ruckdeschel, Anna, John, Mara, Riedel, Angela, Hüper, Sebastian, Peter, Jessica, Walter, Wencke, Haertle, Larissa, Meggendorfer, Manja, Topp, Max S., Rosenwald, Andreas, Da Via, Matteo Claudio, Bolli, Niccolo, Weinhold, Niels, Einsele, Hermann, Haferlach, Claudia, Kortüm, K. Martin, and Rasche, Leo

Published
2021
Full Text
View/download PDF

7. Salvage therapy with “Dara‐KDT‐P(A)CE” in heavily pretreated, high‐risk, proliferative, relapsed/refractory multiple myeloma

Author

Zhou, Xiang, primary, Ruckdeschel, Anna, additional, Peter, Jessica, additional, Böckle, David, additional, Hornburger, Hannah, additional, Danhof, Sophia, additional, Steinhardt, Maximilian Johannes, additional, Heimeshoff, Larissa, additional, Einsele, Hermann, additional, Kortüm, Klaus Martin, additional, and Rasche, Leo, additional

Published
2021
Full Text
View/download PDF

8. Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, additional, Munawar, Umair, additional, Han, Seungbin, additional, Zhou, Xiang, additional, Vogt, Cornelia, additional, Fernández, Rafael Alonso, additional, Bittrich, Max, additional, Ruiz-Heredia, Yanira, additional, Da Viá, Matteo, additional, Zovko, Josip, additional, Garitano-Trojaola, Andoni, additional, Bolli, Niccolò, additional, Ruckdeschel, Anna, additional, Stühmer, Thorsten, additional, Chatterjee, Manik, additional, Kull, Miriam, additional, Krönke, Jan, additional, Agirre, Xabier, additional, Martin-Subero, Jose I., additional, Raab, Peter, additional, Einsele, Hermann, additional, Rasche, Leo, additional, Martinez-Lopez, Joaquin, additional, Haaf, Thomas, additional, and Kortüm, K. Martin, additional

Published
2021
Full Text
View/download PDF

10. Salvage therapy with "Dara‐KDT‐P(A)CE" in heavily pretreated, high‐risk, proliferative, relapsed/refractory multiple myeloma.

Author

Zhou, Xiang, Ruckdeschel, Anna, Peter, Jessica, Böckle, David, Hornburger, Hannah, Danhof, Sophia, Steinhardt, Maximilian Johannes, Heimeshoff, Larissa, Einsele, Hermann, Kortüm, Klaus Martin, and Rasche, Leo

Subjects
MULTIPLE myeloma, SALVAGE therapy, CHIMERIC antigen receptors, LACTATE dehydrogenase, PROGRESSION-free survival
Abstract

The multi‐agent therapy "VDT‐PACE" represents an established regimen in relapsed/refractory multiple myeloma (RRMM). Here, we report on our experience with a "modified VDT‐PACE" incorporating new generation anti‐MM agents daratumumab and carfilzomib ("Dara‐KDT‐P(A)CE"). We retrospectively analyzed 38 patients with RRMM treated with "Dara‐KDT‐P(A)CE". The median age was 62 (range 45–82) years, and the patients were heavily pretreated with a median of 5 (range 2–12) prior lines of therapy. Twenty‐one (55%) patients suffered from penta‐refractory MM. High‐risk cytogenetics was present in 31 (81%) patients. The patients received a median of 2 (range 1–10) cycles of this therapy, and the overall response rate (ORR) was 70%. Patients with penta‐refractory MM and high‐risk cytogenetics showed similar ORR of 65% and 79%, respectively. The median progression‐free survival (PFS) and overall survival were 4.1 (95% CI 2.7–5.4) and 8.4 (95% CI 6.7–10.0) months, respectively. Patients with lactate dehydrogenase >250 IU/L showed significantly shorter PFS in comparison with others patients (p = 0.006). We used this regimen as bridging therapy prior to chimeric antigen receptor T‐cell infusion in four patients. In conclusion, "Dara‐KDT‐P(A)CE" is an effective salvage therapy for patients with heavily pretreated, multi‐refractory, high‐risk RRMM lacking alternative options. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma

Author

Solimando, Antonio, primary, Brandl, Andreas, additional, Katharina, Mattenheimer, additional, Graf, Carolin, additional, Ritz, Miriram, additional, Ruckdeschel, Anna, additional, Stühmer, Thorsten, additional, Rudelius, Martina, additional, Frassanito, Maria Antonia, additional, Andreas, Rosenwald, additional, Jakob, Franz, additional, Vacca, Angelo, additional, Einsele, Hermann, additional, and Beilhack, Andreas, additional

Published
2016
Full Text
View/download PDF

13. École de Paris global

Author

Ruckdeschel, Annabel

Subjects
abstraction, Ecole de Paris, art market, thema EDItEUR::A The Arts::AB The arts: general topics::ABA Theory of art
Abstract

It is a frequently told story that Paris was the world center of art at the beginning of the 20th century. This book asks what contribution exhibitions between 1921 and 1946 made to the development and dissemination of this narrative. It develops a transcultural perspective on the exhibitions in the cafés of the Montparnasse district of Paris and the international exhibitions of the "École de Paris".

Published
2024
Full Text
View/download PDF

15. Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Author

Ruckdeschel, Anna, Sabrina, Koemm, Topp, Max S., Greil, Richard, Melchardt, Thomas, Lenz, Georg, Kerkhoff, Andrea, Shumilov, Evgenii, Hess, Georg, Baumgaertner, Marta, Thurner, Lorenz, Age Kos, Igor, Mayer, Stephanie, Ayuk, Francis A., Krause, Rolf, Herling, Marco, Vucinic, Vladan, Chapuy, Claudia, Illerhaus, Gerald, Knott, Markus, Viardot, Andreas, Grunenberg, Alexander, Dietrich, Sascha, Caille, Leandra, Tometten, Mareike C., Cho, Hyunyee Rosa, Scholz, Julia, Mueller, Fabian, Prochazka, Katharina, Chapuy, Bjoern, Böckle, David, von Tresckow, Bastian, Schub, Natalie, Gelbrich, Götz, Einsele, Hermann, and Duell, Johannes

Abstract

Background

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results